Press Release Oct 24 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received approval from Health Canada for Mesalamine suppositories, which are used to treat ulcerative proctitis. The approval allows Zydus to manufacture these suppositories at its facility in Changodar, Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 06 2025
- Press Release Oct 01 2025
- Press Release Sep 23 2025
- Press Release Sep 21 2025
- Press Release Sep 15 2025
Later from Zydus Lifesciences
- Press Release Oct 29 2025
- Press Release Nov 04 2025
- Press Release Nov 05 2025
- Press Release Nov 06 2025
- Press Release Nov 07 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences